Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3481 - The prognostic role of gender and MGMT methylation status in glioblastoma patients: the female power

Date

10 Sep 2017

Session

Poster display session

Topics

Translational Research;  Central Nervous System Malignancies

Presenters

Alicia Tosoni

Citation

Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366

Authors

A. Tosoni1, E. Franceschi1, R. Depenni2, B. Urbini3, M. Faedi4, M. Michiara5, C. Biasini6, E. Giombelli7, G. Pavesi8, F. Zanelli9, M.A. Cavallo10, L. Tosatto11, A. Fioravanti12, E. Zunarelli13, G. Lanza14, D. Bartolini15, E.M. Silini16, A.A. Brandes1

Author affiliations

  • 1 Medical Oncology, Ausl / Irccs Institute Of Neurological Sciences, Bellaria Hospital, 40139 - Bologna/IT
  • 2 Department Of Oncology, Modena University Hospital, 41124 - Modena/IT
  • 3 Clinical Oncology Unit, St Anna University Hospital, Ferrara/IT
  • 4 Department Of Oncology And Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - IRCCS, Cesena/IT
  • 5 Department Of Medical Oncology, University Hospital of Parma, Parma/IT
  • 6 Department Of Oncology And Hematology, Oncology Unit, Azienda Ospedaliera Guglielmo da Saliceto, Piacenza/IT
  • 7 Neurosurgery, Hospital and University of Parma, Parma/IT
  • 8 Department Of Neurosurgery, Ospedale S. Agostino-Estense, Modena/IT
  • 9 Department Of Medical Oncology, Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, 42100 - Reggio Emilia/IT
  • 10 Department Of Neurosurgery, St Anna University Hospital, Ferrara/IT
  • 11 Neurosurgery, Bufalini Hospital, Cesena/IT
  • 12 Neurosurgery, Ausl / Irccs Institute Of Neurological Sciences, Bellaria Hospital, 40139 - Bologna/IT
  • 13 Department Of Pathology, University Hospital, Modena, Modena/IT
  • 14 Department Of Pathology, S. Anna University Hospital and University of Ferrara, Ferrara/IT
  • 15 Department Of Pathology, Bufalini Hospital, Cesena/IT
  • 16 Departments Of Pathology, University Hospital, Parma, Parma/IT
More

Resources

Abstract 3481

Background

Glioblastoma (GBM) remains an incurable disease. Radiotherapy and temozolomide are the backbone of the treatment. Clinical and molecular factors are essential to define prognosis.

Methods

Data on all new cases of primary brain tumors observed from January 1, 2009, to December 31, 2010, in adults residing within the Emilia-Romagna region were recorded in a prospective registry in the Project of Emilia Romagna on Neuro-Oncology (PERNO). We perform a prospective evaluation about prognostic factors in GBM patients treated with temozolomide concurrent with and adjuvant to radiotherapy.

Results

One hundred sixty-nine GBM patients (median age, 60 years; range 29 – 82) were prospectively evaluated. MGMT methylation status was available in 140 patients. Combining gender and MGMT methylation status we obtained four groups of patients: 36 male pts with methylated MGMT (25.7%), 47 male pts with unmethylated MGMT (33.6%), 32 female pts with methylated MGMT (22.9%), 25 female pts with unmethylated MGMT (17.9%). Results of univariate analysis are summarized in the Table. Overall survival (OS) was significantly different between methylated male and methylated female (p = 0.028), methylated male and unmethylated female (p = 0.031), unmethylated male and methylated female (p = 0.002), methylated female and unmethylated female (p 

Conclusions

The median overall survival is consistently higher for female pts with methylated MGMT, treated with temozolomide concurrent with and adjuvant to radiotherapy. When considered simultaneously with MGMT methylation status, gender might impact on clinical outcome and should be considered as a prognostic factor.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.